153 related articles for article (PubMed ID: 31424656)
1. Low expression of TUG1 promotes cisplatin sensitivity in cervical cancer by activating the MAPK pathway.
Wei X; Zhou Y; Qiu J; Wang X; Xia Y; Sui L
J BUON; 2019; 24(3):1020-1026. PubMed ID: 31424656
[TBL] [Abstract][Full Text] [Related]
2. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
3. LncRNA TUG1 aggravates the progression of cervical cancer by binding PUM2.
Duan W; Nian L; Qiao J; Liu NN
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8211-8218. PubMed ID: 31646551
[TBL] [Abstract][Full Text] [Related]
4. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
5. Taurine up-regulated 1 accelerates tumorigenesis of colon cancer by regulating miR-26a-5p/MMP14/p38 MAPK/Hsp27 axis in vitro and in vivo.
Tian L; Zhao ZF; Xie L; Zhu JP
Life Sci; 2019 Dec; 239():117035. PubMed ID: 31697952
[TBL] [Abstract][Full Text] [Related]
6. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
Zhou Q; Hu T; Xu Y
J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
[TBL] [Abstract][Full Text] [Related]
7. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
8. LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI.
Tian P; Feng Y; Tao L
Chem Biol Drug Des; 2024 Jan; 103(1):e14424. PubMed ID: 38230774
[TBL] [Abstract][Full Text] [Related]
9. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
Liu Y; Liu L; Mou ZX
Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
[TBL] [Abstract][Full Text] [Related]
10. Role of microRNA-4739 in enhancing cisplatin chemosensitivity by negative regulation of RHBDD2 in human cervical cancer cells.
Li Y; Zhou Z; Qu J; Gong P; Wei Y; Sun Y
Cell Mol Biol Lett; 2024 Jan; 29(1):20. PubMed ID: 38267862
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration.
Hu Y; Sun X; Mao C; Guo G; Ye S; Xu J; Zou R; Chen J; Wang L; Duan P; Xue X
Cancer Med; 2017 Feb; 6(2):471-482. PubMed ID: 28088836
[TBL] [Abstract][Full Text] [Related]
12. Long Non-Coding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis of Osteosarcoma Cells by Sponging miR-132-3p and Upregulating SOX4 Expression.
Li G; Liu K; Du X
Yonsei Med J; 2018 Mar; 59(2):226-235. PubMed ID: 29436190
[TBL] [Abstract][Full Text] [Related]
13. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2.
Niu Y; Ma F; Huang W; Fang S; Li M; Wei T; Guo L
Mol Cancer; 2017 Jan; 16(1):5. PubMed ID: 28069000
[TBL] [Abstract][Full Text] [Related]
15. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
Mehta H; Ambele MA; Mokgautsi N; Moela P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
17. TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1.
Zhang L; Cheng H; Yue Y; Li S; Zhang D; He R
Cardiovasc Pathol; 2018; 33():6-15. PubMed ID: 29268138
[TBL] [Abstract][Full Text] [Related]
18. [EBF1 Promotes the Sensitivity of Cervical Cancer Cells to Cisplatin via Activating FBN1 Transcription].
Shen NN; Lin JH; Liu PP
Mol Biol (Mosk); 2023; 57(3):503-504. PubMed ID: 37326054
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression.
Jiang H; Hu X; Zhang H; Li W
Radiat Oncol; 2017 Apr; 12(1):65. PubMed ID: 28376901
[TBL] [Abstract][Full Text] [Related]
20. MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway.
Wang N; Hou MS; Zhan Y; Shen XB; Xue HY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7653-7659. PubMed ID: 30536307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
